30-day FRN

44907

Federal Register / Vol. 84, No. 166 / Tuesday, August 27, 2019 / Notices

jspears on DSK3GMQ082PROD with NOTICES

a. Collection and/or storage of donor
and recipient specimens
b. Tracking and reporting of HIV,
HBV, and HCV infection in donors or
recipients
HHS recognizes that the elimination
of a specific label, (e.g., ‘‘increased risk
donor’’) to designate a separate group of
organ donors with specific
characteristics associated with a
relatively small increased risk of donorderived transmission of HIV, HBV, or
HCV is a change to one of the ACBTSA
recommendations for Guideline
revision. HHS also acknowledges the
diversity of opinions expressed during
the deliberations of this committee
regarding whether or not to continue to
use any label to designate this group of
organ donors. HHS has evaluated the
potential advantages and disadvantages
of using such a label for a specific
subset of all organ donors and proposes
the approach outlined above for several
reasons:
1. Designating a subset of organ
donors does not necessarily prevent or
reduce the risk of transmission of
disease (HIV, HBV, or HCV).
2. Next-of-kin interviews used to
identify risk factors may be unreliable.
3. For transplant candidates with endstage organ disease, the risk of severe
morbidity or mortality associated with
HIV, HBV, or HCV transmission as a
result of accepting an IRD organ is less
than the risk of mortality while
remaining on the wait list for another
organ offer.
4. The risk of morbidity or mortality
from HIV, HBV, or HCV transmission
from an IRD organ is less than other
risks of organ transplant-related
complications, including organ
rejection, and infections resulting from
immune suppression.
5. Use of a label to specify an organ
donor group with small risk of disease
transmission (e.g., HIV, HBV, HCV) can
detract from the recognition of other
known clinical attributes in some
donors that can place recipients at even
greater risk for morbidity and mortality.
We seek informed feedback regarding
this proposed approach to revising the
recommendations in the 2013
Guideline, including the feasibility of
the recommended timing of testing for
living and deceased donors.

Dated: August 8, 2019.
Tammy R. Beckham,
Director, Office of Infectious Disease and HIV/
AIDS Policy.

This
proposed information collection was
previously published in the Federal
Register on May 10, 2019, (84 FR 20642)
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Cancer Institute
(NCI), National Institutes of Health, may
not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The National
Cancer Institute’s Introduction to Cancer
Research Careers (ICRC) Application
(NCI), 0925–XXXX, Exp., Date XX/
XXXX, NEW, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The National Cancer
Institute’s (NCI) ICRC fellowship
program supports NCI’s goal of training
cancer researchers for the 21st century.
Applying to the ICRC program through
the ICRC website application is required
in order for undergraduates,
postbaccalaureate, graduate student
candidates to be considered for entry
into the program. The purpose of the
ICRC Application is to assure that
candidates for the ICRC program meet
basic eligibility requirements; to assess
their potential as future scientists; to
determine where mutual research
interests exist; and to make decisions
regarding which applicants will be
proposed and approved for fellowship
awards. The information is for internal
use to make decisions about prospective
fellows and students that could benefit
from the ICRC program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden are 240
hours.

SUPPLEMENTARY INFORMATION:

[FR Doc. 2019–17759 Filed 8–26–19; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request Introduction to
Cancer Research Careers (ICRC)
Application (NCI)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:

Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Agustina Boswell,
Program Coordinator, Office of
Workforce Planning and Development,
National Cancer Institute, 9609 Medical
Center Drive, Room 2E–134, Rockville,
Maryland 20892 or call non-toll-free
number (240) 276–5162 or Email your
request, including your address to:
boswellam@mail.nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
ADDRESSES:

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Type of respondent
Individuals ........................................................................................................

VerDate Sep<11>2014

19:12 Aug 26, 2019

Jkt 247001

PO 00000

Frm 00066

Fmt 4703

Sfmt 4703

Number of
responses per
respondent

120

E:\FR\FM\27AUN1.SGM

1

27AUN1

Average time
per response
(in hours)
1

Total annual
burden hours
120

44908

Federal Register / Vol. 84, No. 166 / Tuesday, August 27, 2019 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents

Type of respondent

Average time
per response
(in hours)

Total annual
burden hours

Individuals ........................................................................................................

240

1

30/60

120

Totals ........................................................................................................

........................

360

........................

240

Patricia M. Busche,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2019–18426 Filed 8–26–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

jspears on DSK3GMQ082PROD with NOTICES

Number of
responses per
respondent

Name of Committee: National Cancer
Institute Special Emphasis Panel; The
Experimental Therapeutics Clinical Trials
Network (UM1/U24).
Date: September 23–24, 2019.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Klaus B. Piontek, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W116, National Cancer Institute, Rockville,
MD 20892–9750, 240–276–5413,
klaus.piontek@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
I (P50).
Date: September 26–27, 2019.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Majed M. Hamawy, Ph.D.,
MBA, Scientific Review Officer, Research
Programs Review Branch, Division of

VerDate Sep<11>2014

19:12 Aug 26, 2019

Jkt 247001

Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Dr., Rm
7W120, Bethesda, MD 20892, 240–276–6457,
mh101v@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2:
Small Grants Program for Cancer Research
(Omnibus R03).
Date: October 4, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Rockville, MD
20850, 240–276–7286, salvucco@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Quantitative Imaging Tools and Co-Clinical
Imaging Resources.
Date: October 11, 2019.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Rockville, MD
20850, 240–276–7684, saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Optimizing
the Management & Outcomes for Cancer
Survivors.
Date: October 15, 2019.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W240, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Rockville, MD
20850, 240–276–5122, hasan.siddiqui@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Program
Project III.
Date: October 16–17, 2019.
Time: 8:00 a.m. to 5:00 p.m.

PO 00000

Frm 00067

Fmt 4703

Sfmt 4703

Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, Nation Institutes of
Health, Rockville, MD 20850, 240–276–5864,
jennifer.schiltz@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Assay
Validation of High Quality Markers for
Clinical Studies in Cancer.
Date: October 17, 2019.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Rockville, MD
20850, 240–276–7684, saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3:
Small Grants Program for Cancer Research
(Omnibus R03).
Date: October 22, 2019.
Time: 7:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Rockville, MD
20850, 240–276–5122, hasan.siddiqui@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Biospecimen Science Approaches.
Date: November 6, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
7W234, Bethesda, MD 20892–9750, 240–276–
6368, Stoicaa2@mail.nih.gov.

E:\FR\FM\27AUN1.SGM

27AUN1